Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by DJDawg on May 02, 2024 8:52am

sigh

What a long process. I wish there were more clarity on the company about what parts take so long. In general I don't mind being patient but I do mind the black void of information where we hear nothing more than that the quarter for BTD has been bumped (again).

I wish TLT were a company that wasn't public and we were all initial investors that didn't have to watch the depressing price action.

The way I see it, there are traders who seem to swing trade a lot of shares back and forth (still under the the same overall ownership I suspect) and create price fear without losing any of their shares since such a low volume stock. The BIGGEST thing that this pattern relies on is fear and the absence of any new information for a while. If this all the information for a while then the price will continue to fall, not because the majority of holders are selling, but because of this back and forth stock volume.

The only things that will prop up the current price, IMO, are:
- patient data update that shows CR's further out that they have collected. 540 on onwards. If they said BTD not ready yet but here is some more data showing that the CRs continue as we expect, that would bump up confidence.
- an update on GBM such as selection of MAB, sites. Something concrete.
- JV announcement of some kind

Without any updates, I fear the price will continue to fall which makes me sad as I'm a big believer in the science but feel disappointed in the black void of non-information about what makes this so slow or why they cannot get money from other sources.

Comment by Eoganacht on May 02, 2024 11:01am
Hi DJDawg - I also hope we will be getting some longer term data as time goes on. 52 patients will have hit the 24 month milestone by the end of 2024. I hope they make that data available as I believe it will show a far better durable response than the competition. There are some clues as to the hold up in today's news release in the description of the roles of the new employees, but, of ...more  
Comment by menoalittle on May 02, 2024 11:27am
What's clear (to me) on this news release is that they are pushing to collate whatever is needed to submit for BTD.  I suspect that they have targeted having a particular amount of information (i.e., on a certain number of patients), which the FDA has probably told them they should (or need to) have for the submission... and once that target is reached... bada bing bada boom... they ...more  
Comment by Longholder99 on May 02, 2024 11:39am
Also wondering of the added personnel is part of a configuration discussed with an as yet informal partner candidate who has BTD as a benchmark for the next step.  
Comment by Alamir1111 on May 02, 2024 11:50am
2023 Central Pathology Laboratory Review - Use of a central pathology laboratory to validate local pathology laboratory resultsIn addition, Theralase® is collecting the survival data for all patients, with central pathology laboratory validation, who have been previously enrolled and provided the primary Study II Treatment and who have demonstrated a CR or IR at any point in time, with ...more  
Comment by Alamir1111 on May 02, 2024 11:54am
2023 In addition, Theralase® is collecting the survival data for all patients, with central pathology laboratory validation, who have been previously enrolled and provided the primary Study II Treatment and who have demonstrated a CR or IR at any point in time, with duration of that CR or IR at 450 days, for submission to the FDA in support of a pre-Break Through Designation ("BTD" ...more  
Comment by Alamir1111 on May 02, 2024 12:21pm
I'm confused these 2 hired persons will provide training  Providing training and support on central pathology analysis of urine cytology and bladder biopsy pathology samples. I guess  all PhD  Pi.s is just all feathers no meat
Comment by TimboBaggins on May 02, 2024 12:26pm
They seem nice but not very influential personnel, one was a lab tech and intern not to long ago but comes with good credentials. I can't think of any real reasons a JV would want to hire two woman for organizing   Possibly this news release was just to inform us the timeline has been moved again?   
Comment by Alamir1111 on May 02, 2024 1:05pm
TB good post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250